|Home | About | Journals | Submit | Contact Us | Français|
We examined whether the effect of APOE genotype on functional brain connectivity is modulated by gender in healthy older human adults. Our results confirm significantly decreased connectivity in the default mode network in healthy older APOE ε4 carriers compared to ε3 homozygotes. More importantly, further testing revealed a significant interaction between APOE genotype and gender in the precuneus, a major default mode hub. Female ε4 carriers showed significantly reduced default mode connectivity compared to either female ε3 homozygotes or male ε4 carriers, whereas male ε4 carriers differed minimally from male ε3 homozygotes. An additional analysis in an independent sample of healthy elderly using an independent marker of Alzheimer’s disease, i.e. spinal fluid levels of tau, provided corresponding evidence for this gender by APOE interaction. Taken together, these results converge with previous work showing a higher prevalence of the ε4 allele among women with Alzheimer’s disease and, critically, demonstrate that this interaction between APOE genotype and gender is detectable in the preclinical period.
The most important known risk factor for Alzheimer’s disease (AD) is the presence of the Apolipoprotein E type 4 allele (APOE ε4) (Strittmatter et al., 1993). Carriers of the ε4 allele have an increased risk of developing AD compared to people that are homozygous for the ε3 allele (the most common APOE genotype) (Farrer et al., 1997). An important observation that tends to be overlooked is that this APOE effect varies with gender. Women are more likely to develop AD than men across most ages and APOE genotypes (Farrer et al., 1997), but this difference is significantly more pronounced in people with the APOE ε3/ε4 genotype, where women increase their risk approximately four-fold and men show little to no increased risk (Payami et al., 1996; Farrer et al., 1997; Bretsky et al., 1999). In addition to having an increased risk for developing AD, female ε4 carriers with mild cognitive impairment (MCI), a precursor to AD, also express more prominent phenotypic features than their male counterparts; for example, lower hippocampal volumes and worse cognitive scores (Fleisher et al., 2005). A large autopsy series found that female ε4 carriers also had the greatest amyloid plaque and neurofibrillary tangle pathology (Corder et al., 2004). To date, this interaction between gender and APOE status, evident in AD risk, MCI phenotypes, and post-mortem data, has not been explored in-vivo in healthy older subjects.
Previous resting state functional magnetic resonance imaging (fMRI) studies have shown functional connectivity changes in the default mode network (DMN) in MCI (Sorg et al., 2007)) and AD (Greicius et al., 2004; Wang et al., 2007; Zhang et al., 2009), and that this default mode functional connectivity deteriorates as the disease progresses (Bai et al., 2011; Damoiseaux et al., 2011). Recent resting state fMRI studies have investigated whether we can detect similar changes in brain functional connectivity in healthy older ε4 carriers (Sheline et al., 2010; Machulda et al., 2011; Trachtenberg et al., 2011; Westlye et al., 2011). Trachtenberg and colleagues found no APOE-related differences in DMN connectivity. The other three studies show significant DMN connectivity differences between ε4 carriers and ε3 homozygotes, although there is substantial variability in their results. None of these studies examined whether the observed default mode functional connectivity differences varied by gender. In this study we examined the effect of APOE genotype and gender on default mode functional connectivity in healthy older subjects. In line with previous research, we expected to see a pattern similar to what we have observed in AD, that is, decreased connectivity in the DMN (Greicius et al., 2004; Damoiseaux et al., 2011), with the greatest effect in female ε4 carriers. In order to obtain convergent evidence for these imaging findings we also tested the same model in an analysis of spinal fluid protein levels in healthy older controls from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset.
Healthy older adults were recruited as part of longitudinal study of normal aging at the University of California, San Francisco (UCSF). All participants provided informed consent according to the Declaration of Helsinki and the Institutional Review Board at UCSF approved the procedures. Exclusion criteria for this study were the following: left- handedness; any significant medical, neurological or psychiatric illness; a history of brain damage; use of psychoactive medication; poor data quality; and carrying an ε2 allele. APOE ε2 may have a protective effect against developing AD (Scott et al., 1997), therefore we have excluded these subjects from our analyses. Resting state fMRI data and APOE genotype were available for 234 participants. Of these 234 participants, 27 were excluded due to left-handedness; 22 due to poor data quality (excessive head motion; significant signal loss; and partial brain coverage); 36 due to use of psychoactive medication; and 18 for carrying an ε2 allele. This left us with a total of 131 participants that were included. Of these 131 participants, 43 were ε4 carriers, of which 4 were ε4 homozygotes (2 male and 2 female) and 39 were ε3/ε4’s (24 male and 15 female), and 88 were ε3 homozygotes (34 male and 54 female), see table 1 for demographics.
All participants underwent an extensive neuropsychological assessment. For this study we only considered the results of the mini-mental state examination and the neuropsychological tests targeting memory function: the California Verbal Learning Test, both immediate and delayed recall; and the recall of the Benson Complex Figure. Raw test scores were tested for differences between APOE genotype, gender, and the interaction between the two using a multivariate analysis of variance, with p<0.05.
APOE single nucleotide polymorphism (SNP) genotyping was carried out by Real Time polymerase chain reaction (PCR), on an Applied Biosystems 7900HT Real Time PCR machine using the Taqman SNP Genotyping Assay for rs429358 and rs7412 with identification numbers C___3084793_20 and C____904973_10, respectively (Applied Biosystems, Foster City, CA). The protocol was followed as outlined in the manufacturer’s instructions, and every assay was performed in duplicate. In addition to a standard curve amplification protocol, an allelic discrimination step was added to facilitate the contrast between the two alleles and their respective reporter dyes. Sequence Detection Systems Software version 2.3 was used to analyze the SNP genotyping data.
Functional MRI scanning was performed at the UCSF Neuroscience Imaging Center on a 3 Tesla Siemens Tim Trio scanner using a standard 12-channel head coil. Thirty-six interleaved axial slices (3 mm thick with a gap of 0.6 mm) were imaged parallel to the plane connecting the anterior and posterior commissures using a T2*-weighted echo planar sequence (repetition time (TR): 2000 ms; echo time (TE): 27ms; flip angle (FA): 80°; voxel size: 2.5 × 2.5 × 3.6 mm). The field of view was 230×230mm, and the matrix size was 92×92. All subjects underwent an 8-minute resting state fMRI scan after being instructed only to remain awake with their eyes closed. A volumetric magnetization prepared rapid gradient echo (MPRAGE) MRI sequence was used to obtain a T1- weighted image of the entire brain in saggital slices (repetition time, 2300 ms; echo time, 2.98 ms; inversion time, 900 ms; flip angle, 9 degrees). The images were reconstructed as a 160×240×256 matrix with 1×1×1 mm spatial resolution.
Anatomical data was analyzed with FSL-VBM, a voxel-based morphometry style analysis (Ashburner and Friston, 2000; Good et al., 2001) carried out with FSL tools (Smith et al.). First, anatomical images were brain-extracted using BET (Smith, 2002). Next, tissue-type segmentation was carried out using FAST4 (Zhang et al., 2001). The resulting grey-matter partial volume images were then aligned to MNI152 standard space using the affine registration tool FLIRT (Jenkinson and Smith, 2001; Jenkinson et al., 2002), followed by nonlinear registration using FNIRT (Andersson 2007, FMRIB technical reports TR07JA1 and TR07JA2, available at: www.fmrib.ox.ac.uk/analysis/techrep), which uses a b-spline representation of the registration warp field (Rueckert et al., 1999). For the use of grey matter volume as a voxel-wise regressor in the fMRI data analysis, a 4D image was created by concatenating every individual’s standard space grey matter image. For the direct comparison of grey matter volume, the individual standard space grey matter images were averaged to create a study-specific template, to which the native grey matter images were then non-linearly re-registered. The registered partial volume images were then modulated (to correct for local expansion or contraction), by dividing by the Jacobian of the warp field. The modulated segmented images were then smoothed with an isotropic Gaussian kernel with a sigma of 3 mm. Finally, to test for significant differences between ε4 carriers and ε3 homozygotes, a voxel-wise general linear model was applied using permutation-based non-parametric testing, using TFCE as implemented in FSL (Smith and Nichols, 2009), and p<0.05 family-wise error corrected.
Image preprocessing was carried out using tools from FMRIB’s Software Library (FSL, version 4.1) (Smith et al., 2004). The following pre- statistics processing was applied: motion correction (Jenkinson et al., 2002); removal of non-brain structures (Smith, 2002); spatial smoothing using a Gaussian kernel of 6mm full width at half maximum; mean-based intensity normalization of all volumes by the same factor (i.e. 4D grand-mean scaling in order to ensure comparability between data sets at the group level); high-pass temporal filtering (Gaussian-weighted least-squares straight line fitting, with sigma = 75.0s); and Gaussian low-pass temporal filtering (sigma = 2.8s). After pre-processing the functional scan was first aligned to the individual’s high resolution T1-weighted image, which was subsequently registered to the MNI152 standard space (average T1 brain image constructed from 152 normal subjects at Montreal Neurological Institute) using affine linear registration (Jenkinson et al., 2002). To perform voxel-wise between group comparisons of resting state connectivity, the dual regression technique as described in (Filippini et al., 2009; Veer et al., 2010; Damoiseaux et al., 2011) was used. This approach entails three steps: First, creating data-driven population specific spatial maps showing large-scale connectivity patterns, by running group independent component analysis (ICA) on the concatenated resting state data of equal numbers of ε4 carriers, ε3 homozygotes, males and females (17 subjects per group; 68 total). Equal numbers of subjects per sub-group were used here to avoid introducing bias in the creation of the connectivity networks of interest. The dataset was decomposed into 30 independent components. Second, performing the actual dual regression by (i) using all the 30 independent components in a linear model fit (spatial regression) against all the 131 individual datasets, resulting in specific time courses for each independent component and subject, and (ii) using these time courses in a linear model fit (temporal regression) against the individual’s resting state data to estimate subject-specific spatial maps. Lastly, performing voxel-wise between group statistical testing on the subject-specific spatial maps using nonparametric permutation testing (5000 permutations) (Nichols and Holmes, 2002). To control for differences in grey matter volume, the individual grey matter partial volume maps were included as a voxel-wise regressor in the between-group comparison, as described by (Oakes et al., 2007) and implemented in FSL.
The DMN and a control network in which we did not expect to find any changes (i.e. the primary visual network) were selected for between-group analyses. In line with previous observations (Damoiseaux et al., 2011; Westlye et al., 2011), the default-mode network was divided into three sub-networks (referred to here as the anterior, posterior, and ventral DMNs), identified by visual inspection of the group ICA. In order to assess any potential differences in modulation of these networks, we included all three networks in the analysis plus the primary visual network (identified by visual inspection as a single independent component). See figure 1 for a visual representation of all the networks included in the analyses. The fractionation of the DMN into several sub-networks has been observed in multiple previous studies that either used a different methodology (i.e. seed-based correlations) and/or studied a different population (i.e. younger healthy adults) (Uddin et al., 2009; Andrews-Hanna et al., 2010; Littow et al., 2010; Westlye et al., 2011). In addition, sub-divisions of the default mode system have been associated with distinct cognitive functions (Uddin et al., 2009; Andrews-Hanna et al., 2010; Qin et al., 2011; Whitfield-Gabrieli et al., 2011). We therefore believe that this fractionation is not merely a methodological artifact, but that it represents resting state networks with distinct functional attributes.
To find significant differences between ε4 carriers and ε3 homozygotes, a voxel-wise general linear model was applied using permutation-based non-parametric testing, using TFCE with p<0.05 family-wise error corrected, spatially masked with the thresholded group ICA component in question (posterior probability threshold of p>0.5), and a cluster size greater than 10 voxels. Given our a priori hypothesis and the reduced n when splitting by gender, we used TFCE with a more lenient threshold of p<0.01 uncorrected, spatially masked with the thresholded group ICA component in question, and a cluster size greater than 10 voxels, for the genotype by gender interaction analysis and subsequent post-hoc comparisons.
Data used in this part of the study were obtained from the ADNI database (adni.loni.ucla.edu). The primary goal of ADNI has been to test whether serial MRI, positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCIand early AD. Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials.
ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to participate in the research, approximately 200 cognitively normal older individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years and 200 people with early AD to be followed for 2 years. These initial goals were met and the ADNI project has now been extended as ADNI-2.
Within the ADNI database, three separate spreadsheets hold cerebrospinal fluid (CSF) measures; for our analyses we used the original ADNI baseline data from the ‘upennbiomark’ spreadsheet. In this spreadsheet 114 healthy controls have CSF data. Out of these 114 subjects, 21 were ε2 carriers and therefore excluded from our analyses. The remaining subjects were included in our analysis, out of these 93 subjects, 26 were ε4 carriers (2 ε4 homozygotes, 1 male and 1 female; and 24 ε3/ε4’s, 16 male and 8 female) and 67 were ε3 homozygotes (32 male and 35 female) (see table 1 for demographics).
CSF samples were collected at different ADNI sites as described in the ADNI procedures manual (http://www.adni-info.org/). It was then shipped overnight on dry ice to the ADNI Biomarker Core laboratory at the University of Pennsylvania Medical Center. All analyses, as described in Shaw and colleagues (2009), were performed at this location. Mean levels of total tau, amyloid ß1-42 (Aß1-42), and phosphotau (p-tau), in pg/ml, were tested for differences between APOE genotype, gender, and the interaction between the two, using a multivariate analysis of variance, with p<0.05. Subsequent post-hoc comparisons were performed using the Mann- Whitney U test (one-tailed).
We did not find a significant difference between APOE groups in either age or years of education. The distribution of gender across the APOE groups did differ (Pearson Chi-Square, p=0.019). No interaction between APOE genotype and gender was observed for any of these measures. See table 1 for details.
No significant between-group differences or APOE genotype by gender interactions were found for mini-mental state examination scores or memory performance, as measured with the California Verbal Learning Test, immediate and delayed recall; and the recall of the Benson Complex Figure (see table 1).
We first compared functional connectivity within our four networks between all ε4 carriers and all ε3 homozygotes, while correcting voxel-wise for grey matter volume. We found decreased connectivity in ε4 carriers compared to ε3 homozygotes in two large frontal clusters of the anterior DMN (see figure 2A, and table 2), and in a posterior cingulate cluster of the posterior DMN (see figure 2B, and table 2), using ‘Threshold-Free Cluster Enhancement’ (TFCE) and a p<0.05 family- wise error correction. No differences were observed in the opposite direction, and no differences were observed in either the ventral DMN or the primary visual network.
To visualize the distribution of the observed effect across genotype and gender, we extracted the mean parameter estimate per group for a significant cluster in each network that showed significant differences between ε4 carriers and ε3 homozygotes (note: these are the individual values before the grey matter volume correction is applied). For the anterior DMN we selected a representative cluster in the right anterior cingulate gyrus, and for the posterior DMN the left posterior cingulate gyrus. In both clusters the ε4 women have the lowest mean value (see bar graphs in figure 2). The difference across both genotype (p<0.001) and gender (p=0.005) is significant for the anterior cingulate gyrus. For the posterior cingulate gyrus only the difference across genotype is significant (p=0.001).
We then tested voxel-wise for an APOE by gender interaction in the anterior and posterior DMNs, the two networks that showed an ε4 effect, again correcting voxel-wise for grey matter volume. This analysis revealed a significant interaction in the precuneus, a major hub within the posterior DMN (Hagmann et al., 2008) (see figure 3 and table 3), using TFCE and p<0.01 uncorrected. The bar graph in figure 3 shows the distribution across genotype and gender for this region. Not surprisingly the interaction was significant (p<0.001), but the main effects of genotype and gender were not. No significant interaction between APOE genotype and gender was observed in the anterior DMN. Given the significant interaction in the posterior DMN, post-hoc voxel-wise testing was performed for this network (using TFCE and p<0.01 uncorrected) for the following three specific contrasts: female ε3 homozygotes > female ε4 carriers; male ε3 homozygotes > male ε4 carriers; and male ε4 carriers > female ε4 carriers. The results showed the most prominent reduction in posterior default mode functional connectivity in female ε4 carriers compared to female ε3 homozygotes, mainly in a large (>2000 voxel) cluster encompassing the cuneal cortex, precuneus and posterior cingulate gyrus. Male ε4 carriers showed decreased posterior default mode connectivity only in a small (16 voxel) cluster in the left superior parietal cortex compared to male ε3 homozygotes. In addition, female ε4 carriers also showed reduced functional connectivity compared to male ε4 carriers in a cuneus/precuneus cluster of the posterior DMN. See figure 4 and table 3 for specifics of the post-hoc results.
We also tested the effect of ε4 on grey matter volume. No significant between-group differences or APOE genotype by gender interactions were found.
In order to obtain convergent evidence for the imaging findings we also tested the same model in an analysis of CSF protein levels in a total of 93 healthy older controls from the ADNI dataset. As with the imaging dataset, we did not find a significant difference between APOE groups in either age or years of education and there were no significant interactions between APOE genotype and gender for either measure. As has been shown previously (Shaw et al., 2009), we found a difference between ε4 carriers and ε3 homozygotes on all three CSF protein measures, total tau (p=0.022), Aß1-42 (p<0.001), and p-tau (p=0.020). In addition, we found a significant APOE genotype by gender interaction for CSF total tau levels (p=0.024), see figure 5. CSF total tau levels were highest in female ε4 carriers (mean 99 ± 56 pg/ml) and lowest in female ε3 homozygotes (mean 65 ± 21 pg/ml), which was a significant difference (p=0.046). The same comparison in the men showed no significant differences between the male ε4 carriers (mean 72 ± 28 pg/ml) and the male ε3 homozygotes (mean 71 ± 32 pg/ml; p=0.446). No significant differences were found in the other pairwise contrasts: female vs. male ε4 carriers (p=0.144) and female vs. male ε3 homozygotes (p=0.319). No significant interaction was observed for either Aß1-42 (p=0.418) or pTau (p=0.645).
APOE ε4 is a potent AD risk factor. In the normal population 10-15% of people carry the ε4 allele; among AD patients, up to 65% are ε4 carriers (Saunders et al., 1993; Farrer et al., 1997). The mechanism through which ε4 exerts its effect remains elusive, but possibilities include, promotion of tau hyperphosphorylation, reduction of beta-amyloid clearance, and inhibition of neurite outgrowth (Kim et al., 2009). Previous studies of AD risk have shown that the ε4 effect is more pronounced in females (Payami et al., 1996; Farrer et al., 1997; Bretsky et al., 1999). With notable exceptions (Corder et al., 2004; Fleisher et al., 2005; Lehmann et al., 2006), most studies have ignored this gender effect. No previous studies have investigated whether the interaction between gender and APOE is detectable in healthy adults. Here we have shown that this interaction is detectable in healthy older adults using two distinct AD biomarkers in two independent samples.
DMN connectivity is a well-replicated imaging biomarker of AD (Greicius et al., 2004; Buckner et al., 2005; Damoiseaux et al., 2011). Our most compelling imaging results demonstrate an APOE genotype by gender interaction on posterior DMN connectivity. The precuneus/cuneus region of the posterior DMN showed a significant interaction, with the greatest reduction of functional connectivity in female ε4 carriers (Figure 3). Post-hoc testing was most notable for a 2000+ voxel cluster in the posterior cingulate/precuneus showing reduced connectivity in female ε4 carriers compared to female ε3 homozygotes (Figure 4A, Table 3). The same comparison in males only showed reduced connectivity in ε4 carriers in a small DMN cluster (Figure 4B, Table 3). The small size and unusual location (not a core DMN region) of this cluster lead us to interpret this finding cautiously and strengthen our hypothesis that the ε4 effect is mainly driven by female carriers. Comparing female and male ε4 carriers revealed a decrease in female ε4 carriers in three small but more strategically located DMN clusters (Figure 4C, Table 3). In structural and functional connectivity analyses, the posterior cingulate/precuneus region is consistently found to be a core node in the DMN (Hagmann et al., 2008; Buckner et al., 2009). This region is structurally connected to the medial temporal lobes (Greicius et al., 2009), the initial site of tau pathology in AD (Braak and Braak, 1991). It shows reduced glucose metabolism early in AD and in asymptomatic ε4 carriers (Minoshima et al., 1995; Reiman et al., 1996). Lastly, this region shows reduced connectivity in AD patients compared to controls (Greicius et al., 2004) and in MCI patients compared to controls (Sorg et al., 2007). Thus, the interaction of gender and APOE status occurs in a core DMN node and in the node most tightly linked to AD.
In the anterior DMN we did not observe an APOE genotype by gender interaction. However in the cluster highlighted to depict the directionality of the findings (Figure 2A), we saw additive effects of gender and APOE genotype. This indicates that, although there is no APOE genotype by gender interaction, the additive effects of decreased connectivity in ε4 carriers and decreased connectivity in females, renders female ε4 carriers most vulnerable to the observed ε4 effect in this region. The observation of gender differences in resting state functional connectivity, including DMN regions, is consistent with many, but not all (Weissman-Fogel et al., 2010), previous studies on this topic (Liu et al., 2009; Biswal et al., 2010; Allen et al., 2011; Filippi et al., 2012).
Our results may explain the prominent discrepancies in the four previous studies examining the effect of APOE genotype on DMN connectivity in healthy older individuals (Sheline et al., 2010; Machulda et al., 2011; Trachtenberg et al., 2011; Westlye et al., 2011). Sheline and colleagues (2010) found increases and decreases in DMN connectivity in ε4 carriers, Machulda and colleagues (2011) only found decreases, Westlye and colleagues (2011) only found increases, and Trachtenberg and colleagues (2011) found no differences in the DMN but reported differences in two hippocampal networks. The directionality of our findings is most compatible with Machulda and colleagues (2011), who also showed decreased connectivity in ε4 carriers. The discrepancy in the findings between our study and the prior four could be due to the different age ranges. The participants in our and Machulda and colleagues’ studies were older (mean age around 70 and 78, respectively) than those in the other three studies (mean ages around 61, 63, and 45). Perhaps more importantly, the ratio of males to females varied considerably across the previous studies. In the Sheline study there were 29 female and 9 male ε4 carriers, and 43 female and 19 male ε3 homozygotes; in the Machulda study gender was matched across APOE genotype groups, with 21 females and 35 males in each group; in the Westlye study there were 20 female and 13 male ε4 carriers, and 41 female and 21 male ε3 homozygotes; and in the Trachtenberg study there were 17 female and 17 male ε4 carriers and 10 female and 10 male ε3 homozygotes. The discrepancy in findings across these previous studies might therefore be explained by an underlying and unexplored APOE genotype by gender interaction.
We used the ADNI CSF dataset to obtain convergent evidence of an APOE genotype by gender interaction in an independent cohort with an independent biomarker for AD. We found a main effect of APOE on all three markers in the expected direction and an APOE genotype by gender interaction in total tau levels, where female ε4 carriers had significantly elevated levels compared to female ε3 homozygotes while male ε4 carriers and male ε3 homozygotes had nearly identical levels. To our knowledge this is the first report of an APOE genotype by gender interaction in a CSF biomarker of AD. Numerous studies have shown that AD and MCI patients have reduced CSF levels of Aß1-42 and increased levels of p-tau and total tau (Tarawneh and Holtzman, 2010). Shaw and colleagues have previously examined the ADNI healthy control dataset and noted an APOE effect on Aß1-42 levels (reduced in ε4 carriers) and p-tau levels (increased in ε4 carriers), but did not find a significant APOE effect in total tau levels (Shaw et al., 2009). Our analysis differs in that we excluded ε2 carriers and examined an APOE genotype by gender interaction. It is unclear why the APOE genotype by gender interaction was detectable in total tau levels but not in p-tau or Aß1-42 levels, though this might reflect the temporal progression of biomarkers in AD pathology. It is generally accepted that beta- amyloid pathology precedes tau pathology by many years (Jack et al., 2010; Jack et al., 2011). It is possible that p-tau changes precede total tau changes on the pathological progression to AD. This is consistent with the findings in Shaw et al., where healthy ε4 carriers, collapsed across gender, differ from non-ε4 carriers in Aß1-42 levels and p-tau levels but not (yet) in total tau levels. In our analysis, female ε4 carriers, presumably further along in their AD pathology, show changes in Aß1-42 levels, p-tau levels, and total tau levels whereas male ε4 carriers only manifest differences in the first two markers.
No differences or APOE genotype by gender interactions were observed for grey matter volume or memory performance. Changes in DMN functional connectivity and CSF tau protein levels seem to precede changes in brain structure and cognitive performance. This discrepancy suggests that resting-state functional connectivity and CSF protein analyses may therefore be more sensitive than cognitive testing or structural MRI measures as markers of preclinical AD.
Although we show that female ε4 carriers have decreased DMN connectivity and increased CSF tau levels, we can only speculate as to the mechanism(s) behind this interaction. The most obvious possibility would be some interaction between APOE status and sex hormone levels. Hundreds of studies in animals and humans have examined the effect of estrogen loss and replacement on cognition and dementia risk in older women (see (Henderson, 2009) for a recent review). The negative outcome of the Women’s Health Initiative Memory Study, which showed an increased dementia risk in women on estrogen replacement therapy, has only added to the uncertainty regarding estrogen replacement (Shumaker et al., 2004). Regarding our findings, it is notable that the few studies of estrogen and cognition that have stratified by APOE status suggest that APOE status may be critical in evaluating estrogen replacement (Yaffe et al., 2000; Kang and Grodstein, 2010).
We have demonstrated that gender influences the effect of APOE genotype on both DMN connectivity and CSF tau levels, and determined that the detrimental effect of the ε4 allele is most pronounced in females. Our results support previous work showing a higher prevalence of the ε4 allele among women with AD and, more critically, demonstrate that this interaction between APOE genotype and gender is detectable in the preclinical period. Future studies using biomarkers in the preclinical stages of disease should allow us to dissect the environmental, hormonal, and genetic factors that underlie this interaction which appears central to AD pathogenesis.
The authors thank William Irwin, Maria Molfino, and Heidi Jiang for their help with MRI data transfer and preprocessing, and Eric Klein for his help with the APOE genotyping. This work was supported by the Hillblom Foundation, the John Douglas French Alzheimer’s Disease Foundation, the JNA Foundation, and the following grants from the National Institutes of Health: NS073498 and AG032306.
Alzheimer’s Disease Neuroimaging Initiative (ADNI) data: Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging an Bioengineering, and through generous contributions from the following: Abbott; Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles.
Supplementary materials: None
Conflict of Interest: None